Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more
OncoAlert Colloquium Day 4: GI oncology and EONS
OncoAlert Colloquium Day 3: Breast cancer
OncoAlert Colloquium Day 2: Lung cancer and MASCC
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology
Dihydropyrimidine dehydrogenase polymorphisms knocking on the door
Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma
SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups
Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease